This is the authors' abstract. We don't add key points for this paper.
TPC2 is a pathophysiologically relevant lysosomal ion channel that is activated directly by the phosphoinositide PI(3,5)P 2 and indirectly by the calcium ion (Ca 2+ )–mobilizing molecule NAADP through accessory proteins that associate with the channel. TPC2 toggles between PI(3,5)P 2 -induced, sodium ion (Na + )–selective and NAADP-induced, Ca 2+ –permeable states in response to these cues. To address the molecular basis of polymodal gating and ion-selectivity switching, we investigated the mechanism by which NAADP and its synthetic functional agonist, TPC2-A1-N, induced Ca 2+ release through TPC2 in human cells. Whereas NAADP required the NAADP-binding proteins JPT2 and LSM12 to evoke endogenous calcium ion signals, TPC2-A1-N did not. Residues in TPC2 that bind to PI(3,5)P 2 were required for channel activation by NAADP but not for activation by TPC2-A1-N. The cryptic voltage-sensing region of TPC2 was required for the actions of TPC2-A1-N and PI(3,5)P 2 but not for those of NAADP. These data mechanistically distinguish natural and synthetic agonist action at TPC2 despite convergent effects on Ca 2+ permeability and delineate a route for pharmacologically correcting impaired NAADP-evoked Ca 2+ signals.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Saito et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: